A Real-world Clinical Study on the Treatment of Menopausal Syndrome With Liuwei Dihuang Pills

Launched by CHINA ACADEMY OF CHINESE MEDICAL SCIENCES · Mar 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a natural herbal treatment called Liuwei Dihuang Pills on menopausal syndrome in women. Menopausal syndrome can cause symptoms like hot flashes, mood swings, and difficulty sleeping, which can affect daily life. The goal of this study is to see how well these pills work and to determine if they are a safe and effective option for women aged 45 to 55 who have been diagnosed with a specific type of kidney deficiency known as Kidney Yin Deficiency Syndrome.

To be eligible for the study, participants must be women between 45 and 55 years old who are experiencing menopausal symptoms and are currently using Liuwei Dihuang Pills. However, those with certain health conditions, such as allergies to the ingredients, other serious illnesses, or previous surgeries affecting the reproductive system, will not be able to participate. If someone decides to join the study, they can expect to contribute to understanding how this treatment may help others while being monitored for any effects during the trial. The study is not yet recruiting participants, so there will be more information available soon for those interested.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Age: 45-55 years old
• • 2. Patients with menopausal syndrome using Liuwei Dihuang Pills
• • 3. Kidney Yin Deficiency Syndrome
• Exclusion Criteria:
• • 1. Individuals allergic to any components of the drug or excipients;
• • 2. Individuals with other endocrine diseases;
• • 3. Individuals with organic lesions of the reproductive system;
• • 4. Individuals who have undergone bilateral oophorectomy, hysterectomy, or have ovarian dysfunction;
• • 5. Individuals with endometrial hyperplasia or unexplained vaginal bleeding;
• • 6. Individuals with malignant tumors, hematologic, or immune system diseases;
• • 7. Individuals with severe cardiovascular, cerebrovascular, liver, or kidney diseases (e.g., serum transaminase levels more than 1.5 times the upper limit of normal, serum creatinine above the upper limit of normal);
• • 8. Individuals with psychiatric disorders or dependence on alcohol or drugs;
• • 9. Individuals with mental illness or communication barriers;
• • 10. Individuals with other conditions that, in the investigator's judgment, may reduce the likelihood of enrollment or complicate the study process are not suitable for participation in this clinical research.